Skip to content

Arvinas ARVN Current ratio

Current ratio at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-0.3×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
9.5×+3.9×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
18.3×+13.0×
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
2.3×-1.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on the most recent quarter.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's current ratio?
Arvinas (ARVN) reported current ratio of 5.4× in Q1 2026.
How has Arvinas's current ratio changed year-over-year?
Arvinas's current ratio increased by 18.9% year-over-year, from 4.6× to 5.4×.
What is the long-term trend for Arvinas's current ratio?
Over 5 years (2020 to 2025), Arvinas's current ratio has grown at a -19.2% compound annual growth rate (CAGR), from 14.3× to 4.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.